Affiliation:
1. P. A. Hertsen Moscow Oncology Research Institute — Branch of the National Medical Research Radiological Centre
2. P. A. Hertsen Moscow Oncology Research Institute — Branch of the National Medical Research Radiological Centre; National Medical Research Radiological Centre; Peoples’ Friendship University of Russia
Abstract
Breast cancer is the most common female cancer and cause of death from cancer in women worldwide. Overexpression of HER2 / neu, which is an unfavorable predictor associated with a more aggressive course of the disease, is detected in every 5th breast cancer patient. Over the past 20 years, targeted therapy has changed the natural course of breast cancer. However, standard neoadjuvant chemotherapy regimens in combination with targeted therapy are poorly tolerated and, therefore, are considered suboptimal. Evidently, not all patients require such toxic treatment regimens. In this review article, we present our view whether neoadjuvant therapy can be de-escalated in patients with HER2‑positive breast cancer.
Publisher
Russian Society of Clinical Oncology
Reference40 articles.
1. Состояние онкологической помощи населению России в 2021 г, под редакцией А. Д. Каприна, В. В. Старинского, А. О. Шахзадовой. Москва 2022 г, с. 23–25.
2. Cronin KA, Harlan LC, Dodd KW, Abrams JS, Ballard-Barbash R. Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US. Cancer Invest. 2010 Nov ; 28 (9) : 963–8. doi: 10.3109/07357907.2010.496759. PMID: 20690807 ; PMCID: PMC5094051.
3. Slamon, D. J. ; Clark, G. M. ; Wong, S. G. ; Levin, W. J. ; Ullrich, A. ; McGuire, W. L. Human breast cancer : Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235, 177–182.
4. Slamon, D. J. ; Leyland-Jones, B. ; Shak, S. ; Fuchs, H. ; Paton, V. ; Bajamonde, A. ; Fleming, T. ; Eiermann, W. ; Wolter, J. ; Pegram, M. ; et al. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. New Engl. J. Med. 2001, 344, 783–792.
5. Клинические рекомендации «Рак молочной железы» Общероссийский национальный союз «Ассоциация онкологов России» • Общероссийская общественная организация «Российское общество клинической онкологии» • Общероссийская общественная организация «Российское общество онкомаммологов», 2021 г.